{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:21:55Z","timestamp":1792077715542,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.dsx.2023.102875","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:08:41Z","timestamp":1697062121000},"page":"102875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE)"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-3102","authenticated-orcid":false,"given":"Ashu","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Sudhayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas C.","family":"Schaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Jude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4093\/dmj.2018.0060","article-title":"Diabetes mellitus and cause-specific mortality: a population-based study","volume":"43","author":"Li","year":"2019","journal-title":"Diab Metabol J"},{"key":"10.1016\/j.dsx.2023.102875_bib2","series-title":"Guidance for industry: diabetes mellitus \u2013 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver spring, MD","volume":"vols. 1\u20135","year":"2008"},{"issue":"19","key":"10.1016\/j.dsx.2023.102875_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9149(93)90101-H","article-title":"Use of composite endpoints in thrombolysis trials of acute myocardial infarction","volume":"72","author":"Braunwald","year":"1993","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.dsx.2023.102875_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jclinepi.2006.10.020","article-title":"Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns","volume":"60","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.dsx.2023.102875_bib6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2023.102875_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/pdi.1960160605","article-title":"Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic","volume":"16","author":"Elhadd","year":"1999","journal-title":"Practical Diabetes Int"},{"key":"10.1016\/j.dsx.2023.102875_bib8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-2004-830408","article-title":"High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes","volume":"112","author":"Lange","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.dsx.2023.102875_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","article-title":"Intermittent claudication: a risk profile from the Framingham heart study","volume":"96","author":"Murabito","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib10","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2337\/dc13-2432","article-title":"Diabetes and vascular disease in different arterial territories","volume":"37","author":"Shah","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","article-title":"Peripheral artery disease: epidemiology and global perspectives","volume":"14","author":"Fowkes","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/diacare.11.6.464","article-title":"Progression of lower-extremity arterial occlusive disease in type II diabetes mellitus","volume":"11","author":"Beach","year":"1988","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/diacare.26.4.1241","article-title":"Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years","volume":"26","author":"Kallio","year":"2003","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.dsx.2023.102875_bib14","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.2337\/diacare.26.12.3333","article-title":"Peripheral arterial disease in people with diabetes","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2023.102875_bib16","first-page":"C45","article-title":"Effect of insulin therapy on macrovascular risk factors in type 2 diabetes","volume":"22","author":"Boyne","year":"1999","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.dsx.2023.102875_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4239\/wjd.v6.i7.961","article-title":"Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes","volume":"6","author":"Thiruvoipati","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.dsx.2023.102875_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3276","article-title":"Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update)","volume":"36","author":"Hinchliffe","year":"2020","journal-title":"Diab Metabol Res Rev"},{"issue":"8","key":"10.1016\/j.dsx.2023.102875_bib19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","article-title":"Peripheral arterial disease in diabetic and nondiabetic patients","volume":"24","author":"Edward","year":"2001","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2337\/diab.13.4.366","article-title":"Combined clinical and pathologic study of diabetic and nondiabetic peripheral arterial disease","volume":"13","author":"Strandness","year":"1964","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.dsx.2023.102875_bib21","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1096-9136(199703)14:3<214::AID-DIA339>3.0.CO;2-9","article-title":"Results and cost analysis of distal [crural\/pedal] arterial revascularisation for limb salvage in diabetic and non\u2010diabetic patients","volume":"14","author":"Panayiotopoulos","year":"1997","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.dsx.2023.102875_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/dc17-0068","article-title":"Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point?","volume":"40","author":"Marx","year":"2017","journal-title":"Diabetes Care"},{"issue":"9142","key":"10.1016\/j.dsx.2023.102875_bib24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(98)03212-7","article-title":"Evolution of the management of acute myocardial infarction: a 20th century saga","volume":"352","author":"Braunwald","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.dsx.2023.102875_bib25","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamainternmed.2021.5726","article-title":"Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials","volume":"181","author":"O'Fee","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.dsx.2023.102875_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jelectrocard.2018.02.006","article-title":"Linking stroke-induced heart injury and neurogenic atrial fibrillation: a hypothesis to be proven","author":"Sposato","year":"2018","journal-title":"J Electrocardiol"},{"issue":"18","key":"10.1016\/j.dsx.2023.102875_bib27","doi-asserted-by":"crossref","first-page":"J15","DOI":"10.1016\/0002-9149(87)90678-3","article-title":"Neurogenic heart disease: a unifying hypothesis","volume":"60","author":"Samuels","year":"1987","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102875_bib28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2013.842","article-title":"Long-term mortality after stroke among adults aged 18 to 50 years","volume":"309","author":"Rutten-Jacobs","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.dsx.2023.102875_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/STROKEAHA.119.028066","article-title":"First-ever ischemic stroke and incident major adverse cardiovascular events in 93 627 older women and men","volume":"51","author":"Sposato","year":"2020","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2796.1993.tb00746.x","article-title":"Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease","volume":"234","author":"Nyman","year":"1993","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.dsx.2023.102875_bib32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2023.102875_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12471-016-0939-y","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group","volume":"25","author":"Damman","year":"2017","journal-title":"Neth Heart J"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diacare.26.3.855","article-title":"Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study","volume":"26","author":"Vaur","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102875_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijcard.2012.09.128","article-title":"Long-term survival after hospitalization for acute heart failure\u2014differences in prognosis of acutely decompensated chronic and new-onset acute heart failure","volume":"168","author":"Lassus","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib38","article-title":"Prognostic role of prior heart failure hospitalization among patients hospitalized for worsening chronic heart failure","volume":"14","author":"Blumer","year":"2021","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.dsx.2023.102875_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13970","article-title":"Evaluation of heart failure admission as a surrogate for mortality in randomized clinical trials: a meta\u2010analysis","author":"Miyamoto","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.dsx.2023.102875_bib40","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1161\/01.CIR.94.11.3026","article-title":"Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review","volume":"94","author":"Weitz","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2023.102875_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/14746514040040030901","article-title":"Predictors of mortality in patients with peripheral vascular disease. A prospective follow-up study","volume":"3","author":"Missouris","year":"2004","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"14","key":"10.1016\/j.dsx.2023.102875_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102875_bib43","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.dsx.2023.102875_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-016-0446-x","article-title":"Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study","volume":"15","author":"Mohammedi","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2047487313519344","article-title":"Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study","volume":"22","author":"Subherwal","year":"2015","journal-title":"Eur J Prevent Cardiol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102875_bib46","article-title":"Cause of death among patients with peripheral artery disease: insights from the EUCLID trial","volume":"13","author":"Kochar","year":"2020","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.dsx.2023.102875_bib47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2147\/VHRM.S6759","article-title":"Ankle brachial pressure index (ABPI): an update for practitioners","author":"Al-Qaisi","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"10.1016\/j.dsx.2023.102875_bib48","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jvs.2020.11.030","article-title":"A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests used to establish the presence of peripheral arterial disease in people with diabetes","volume":"73","author":"Normahani","year":"2021","journal-title":"J Vasc Surg"},{"issue":"9","key":"10.1016\/j.dsx.2023.102875_bib49","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3390\/jcm9093009","article-title":"Mortality in patients with diabetic foot ulcers: causes, risk factors, and their association with evolution and severity of ulcer","volume":"9","author":"Rubio","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.dsx.2023.102875_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108113","article-title":"Long term outcomes after incident diabetic foot ulcer: multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study: epidemiology of diabetic foot complications study","volume":"162","author":"Rastogi","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.dsx.2023.102875_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/dom.14840","article-title":"Global mortality of diabetic foot ulcer: a systematic review and meta\u2010analysis of observational studies","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.jfas.2016.01.012","article-title":"Mortality after nontraumatic major amputation among patients with diabetes and peripheral vascular disease: a systematic review","volume":"55","author":"Thorud","year":"2016","journal-title":"J Foot Ankle Surg"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijsu.2006.06.027","article-title":"Survival rates in dysvascular lower limb amputees","volume":"4","author":"Kulkarni","year":"2006","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib54","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc10-2341","article-title":"Time-dependent impact of diabetes on mortality in patients after major lower extremity amputation: survival in a population-based 5-year cohort in Germany","volume":"34","author":"Icks","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2023.102875_bib55","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.2337\/dc06-0926","article-title":"DARTS\/MEMO Collaboration. Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes","volume":"29","author":"Schofield","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.dsx.2023.102875_bib56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3928\/0147-7447-19920901-07","article-title":"Energy demands for walking in dysvascular amputees as related to the level of amputation","volume":"15","author":"Pinzur","year":"1992","journal-title":"Orthopedics"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213256","article-title":"Metabolic costs of activities of daily living in persons with a lower limb amputation: a systematic review and meta-analysis","volume":"14","author":"van Schaik","year":"2019","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.dsx.2023.102875_bib58","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.dsx.2023.102875_bib59","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.117.031855","article-title":"Quantifying importance of major risk factors for coronary heart disease","volume":"139","author":"Pencina","year":"2019","journal-title":"Circulation"},{"issue":"7258","key":"10.1016\/j.dsx.2023.102875_bib60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.dsx.2023.102875_bib61","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib62","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","article-title":"Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use","volume":"62","author":"Potier","year":"2019","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib63","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/dom.14671","article-title":"Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial","volume":"24","author":"Barraclough","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib65","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"8","key":"10.1016\/j.dsx.2023.102875_bib66","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.dsx.2023.102875_bib67","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.dsx.2023.102875_bib69","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dsx.2023.102875_bib70","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102875_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-13-49","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study","volume":"13","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102875_bib72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.dsx.2023.102875_bib73","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE. Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2023.102875_bib74","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.dsx.2023.102875_bib75","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.dsx.2023.102875_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"10.1016\/j.dsx.2023.102875_bib77","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.dsx.2023.102875_bib78","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:24:34Z","timestamp":1761729874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123001716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1871402123001716"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102875","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC).","name":"copyright","label":"Copyright"}],"article-number":"102875"}}